TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 84 filers reported holding TCR2 THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.96 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $210 | -69.3% | 140 | -79.6% | 0.00% | – |
Q4 2022 | $684 | -99.7% | 685 | +389.3% | 0.00% | – |
Q3 2022 | $252,000 | -97.0% | 140 | -95.2% | 0.00% | – |
Q2 2022 | $8,413,000 | -96.8% | 2,901 | -96.9% | 0.00% | – |
Q1 2022 | $260,806,000 | -57.6% | 94,495 | -28.4% | 0.00% | -100.0% |
Q4 2021 | $614,631,000 | +822.3% | 131,895 | +1584.3% | 0.00% | – |
Q3 2021 | $66,642,000 | +17.5% | 7,831 | +126.6% | 0.00% | – |
Q2 2021 | $56,713,000 | -89.0% | 3,456 | -85.1% | 0.00% | -100.0% |
Q1 2021 | $513,669,000 | +362.3% | 23,264 | +547.7% | 0.00% | – |
Q4 2020 | $111,101,000 | -9.0% | 3,592 | -40.2% | 0.00% | – |
Q3 2020 | $122,144,000 | +1119.6% | 6,011 | +821.9% | 0.00% | – |
Q2 2020 | $10,015,000 | -64.2% | 652 | -82.0% | 0.00% | – |
Q1 2020 | $27,996,000 | -27.7% | 3,617 | +33.3% | 0.00% | – |
Q4 2019 | $38,742,000 | +91.9% | 2,713 | +102.0% | 0.00% | – |
Q3 2019 | $20,185,000 | +1708.7% | 1,343 | +1621.8% | 0.00% | – |
Q2 2019 | $1,116,000 | – | 78 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |